Healthcare investors can look past the development risk. Global Blood Therapeutics (NASDAQ: GBT) crushed analyst estimates when it reported its first-quarter results on May 6. In its first full quarter on the market, Global Blood's sickle cell disease drug Oxbryta posted $14.1 million in net sales. Read More...
3 Top Pharma Stocks to Buy Right Now
Healthcare investors can look past the development risk. Global Blood Therapeutics (NASDAQ: GBT) crushed analyst estimates when it reported its first-quarter results on May 6. In its first full quarter on the market, Global Blood’s sickle cell disease drug Oxbryta posted $14.1 million in net sales.
Add Comment